These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 12941750)
21. [Three studies in type 2 diabetes: ADOPT Rosiglitazone monotherapy in type 2 diabetes: what indication?]. Roussel R Ann Endocrinol (Paris); 2007 Jun; 68 Suppl 1():28-32. PubMed ID: 17961658 [No Abstract] [Full Text] [Related]
23. Adverse effect of pioglitazone in military personnel and their families: a preliminary report. Vudhironarit T; Benjasuratwong Y; Patarakitvanit S; Temboonkiat S; Satyapan N J Med Assoc Thai; 2009 Feb; 92 Suppl 1():S124-8. PubMed ID: 21299185 [TBL] [Abstract][Full Text] [Related]
24. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Idris I; Warren G; Donnelly R Arch Intern Med; 2012 Jul; 172(13):1005-11. PubMed ID: 22688528 [TBL] [Abstract][Full Text] [Related]
25. [Diabetic edematous maculopathy associated with rosiglitazone treatment: report of a case]. Nyssen V; Hautenauven F; Lekeu Hinostroza JP; Guagnini AP Bull Soc Belge Ophtalmol; 2009; (313):39-44. PubMed ID: 20108571 [TBL] [Abstract][Full Text] [Related]
26. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone. Sarker A; Semple RK; Dinneen SF; O'Rahilly S; Martin SC Diabetes Care; 2004 Nov; 27(11):2577-80. PubMed ID: 15504988 [TBL] [Abstract][Full Text] [Related]
27. Leukopenia and thrombocytopenia caused by thiazolidinediones. Digman C; Klein AK; Pittas AG Ann Intern Med; 2005 Sep; 143(6):465-6. PubMed ID: 16172449 [No Abstract] [Full Text] [Related]
28. Skeletal toxicity of thiazolidinediones. Grey AB Ann Intern Med; 2008 Apr; 148(7):563. PubMed ID: 18378956 [No Abstract] [Full Text] [Related]
30. Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes. Chang TJ; Liu PH; Liang YC; Chang YC; Jiang YD; Li HY; Lo MT; Chen HS; Chuang LM Pharmacogenet Genomics; 2011 Dec; 21(12):829-36. PubMed ID: 21934636 [TBL] [Abstract][Full Text] [Related]
31. Fluid retention with thiazolidinediones: does the mechanism influence the outcome? Lindenfeld J; Masoudi FA J Am Coll Cardiol; 2007 Apr; 49(16):1705-7. PubMed ID: 17448372 [No Abstract] [Full Text] [Related]
34. The rise and fall of rosiglitazone. Nissen SE Eur Heart J; 2010 Apr; 31(7):773-6. PubMed ID: 20154334 [No Abstract] [Full Text] [Related]
35. Distal upper and lower limb fractures associated with thiazolidinedione use. Jones SG; Momin SR; Good MW; Shea TK; Patric K Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952 [TBL] [Abstract][Full Text] [Related]
36. Hepatic injury in a patient taking rosiglitazone. Menees SB; Anderson MA; Chensue SW; Moseley RH J Clin Gastroenterol; 2005 Aug; 39(7):638-40. PubMed ID: 16000935 [TBL] [Abstract][Full Text] [Related]
37. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus. Odom J; Williamson B; Carter L Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427 [No Abstract] [Full Text] [Related]
38. Rosiglitazone and pioglitazone. Beware fractures. Dixit A; Pandey P BMJ; 2009 Sep; 339():b3957. PubMed ID: 19808816 [No Abstract] [Full Text] [Related]
39. Rosiglitazone or pioglitazone in type 2 diabetes? de Vries CS; Russell-Jones DL BMJ; 2009 Aug; 339():b3076. PubMed ID: 19690344 [No Abstract] [Full Text] [Related]